|1.||Carlson, J N: 1 article (03/2001)|
|2.||Glick, S D: 1 article (03/2001)|
|3.||Haskew, R: 1 article (03/2001)|
|4.||Maisonneuve, I M: 1 article (03/2001)|
|5.||Jerussi, T P: 1 article (03/2001)|
|6.||Wacker, J: 1 article (03/2001)|
03/01/2001 - "We evaluated racemic zopiclone, its (S)- and (R)-enantiomers and a metabolite, (S)-desmethylzopiclone, for their actions on locomotor activity, rotarod performance, the elevated plus maze and the Vogel conflict test of anxiety, and electroconvulsive shock-induced seizures duration. "
03/01/2001 - "Zopiclone and its (R)- and (S)-enantiomers reduced locomotor activity, and zopiclone and its (S)-enantiomer disrupted rotarod performance at 10 mg/kg. (S)-desmethylzopiclone did not alter these measures at doses of less than 200 mg/kg. (S)-desmethylzopiclone altered plus maze performance at the lowest dose of all the zopiclone derivatives tested, caused a dose-related effect on the Vogel conflict test and caused a dose-related reduction of electroconvulsive shock-induced seizure durations. "
|1.||Dihydrotachysterol (AT 10)